Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ASBP Aspire Biopharma	$0.59 +64.3%	$0.35	$0.22 ▼ $15.80	$29.22M	0.79	9.81 million shs	464.85 million shs
BCTX Briacell Therap	$0.76 +3.1%	$1.89	$0.61 ▼ $29.40	$5.17M	1.07	1.14 million shs	615,740 shs
PASG Passage Bio	$7.22 +3.9%	$7.07	$5.12 ▼ $26.60	$22.96M	1.81	28,148 shs	57,345 shs
PULM Pulmatrix	$4.71	$6.43	$1.78 ▼ $10.40	N/A	1.45	27,874 shs	11,029 shs

A Guide To High-Short-Interest Stocks

MarketBeat's analysts have just released their top five short plays for August 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ASBP Aspire Biopharma	0.00%	+6.85%	+0.28%	+35,899,900.00%	+35,899,900.00%
BCTX Briacell Therap	0.00%	+3.53%	-7.30%	-76.88%	-91.18%
PASG Passage Bio	0.00%	+10.85%	+25.00%	+16.61%	-54.45%
PULM Pulmatrix	0.00%	-7.10%	-25.65%	-27.54%	+132.02%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ASBP Aspire Biopharma	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
BCTX Briacell Therap	2.8316 of 5 stars	3.5	5.0	0.0	0.0	2.4	0.0	0.6
PASG Passage Bio	3.7757 of 5 stars	3.5	5.0	0.0	0.0	2.6	2.5	1.3
PULM Pulmatrix	1.1812 of 5 stars	0.0	5.0	0.0	0.0	4.1	0.0	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ASBP Aspire Biopharma	0.00	N/A	N/A	N/A
BCTX Briacell Therap	3.00	Buy	$32.00	4,093.97% Upside
PASG Passage Bio	3.00	Buy	$91.75	1,170.78% Upside
PULM Pulmatrix	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest BCTX, PASG, PULM, and ASBP Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/14/2025	PASG Passage Bio	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$260.00 ➝ $67.00
8/13/2025	PASG Passage Bio	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$40.00
6/24/2025	PASG Passage Bio	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$120.00

(Data available from 8/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ASBP Aspire Biopharma	N/A	N/A	N/A	N/A	($2.17) per share	N/A
BCTX Briacell Therap	N/A	N/A	N/A	N/A	($2.20) per share	N/A
PASG Passage Bio	N/A	N/A	N/A	N/A	$19.84 per share	N/A
PULM Pulmatrix	$7.81M	N/A	N/A	N/A	$2.45 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ASBP Aspire Biopharma	-$12.54M	N/A	0.00	∞	N/A	N/A	N/A	-737.96%	N/A
BCTX Briacell Therap	-$4.79M	-$8.32	N/A	N/A	N/A	N/A	-479.97%	-182.26%	10/27/2025 (Estimated)
PASG Passage Bio	-$64.77M	-$18.16	N/A	N/A	N/A	N/A	-103.87%	-59.95%	N/A
PULM Pulmatrix	-$6.94M	-$2.17	N/A	∞	N/A	-122.46%	-97.25%	-88.96%	11/6/2025 (Estimated)

Latest BCTX, PASG, PULM, and ASBP Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2025	Q2 2025	ASBP Aspire Biopharma	N/A	-$0.04	N/A	-$0.04	N/A	N/A
8/12/2025	Q2 2025	PASG Passage Bio	-$4.00	-$2.96	+$1.04	-$2.96	N/A	N/A
8/6/2025	Q2 2025	PULM Pulmatrix	N/A	-$0.42	N/A	-$0.42	N/A	N/A
6/13/2025	Q3 2025	BCTX Briacell Therap	-$1.76	-$1.64	+$0.12	-$1.64	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ASBP Aspire Biopharma	N/A	N/A	N/A	N/A	N/A
BCTX Briacell Therap	N/A	N/A	N/A	N/A	N/A
PASG Passage Bio	N/A	N/A	N/A	N/A	N/A
PULM Pulmatrix	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ASBP Aspire Biopharma	N/A	0.09	0.09
BCTX Briacell Therap	N/A	3.41	3.41
PASG Passage Bio	N/A	3.05	3.05
PULM Pulmatrix	N/A	11.21	11.21

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ASBP Aspire Biopharma	19.17%
BCTX Briacell Therap	15.42%
PASG Passage Bio	53.48%
PULM Pulmatrix	11.84%

Insider Ownership

Company	Insider Ownership
ASBP Aspire Biopharma	48.00%
BCTX Briacell Therap	5.73%
PASG Passage Bio	4.30%
PULM Pulmatrix	0.62%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ASBP Aspire Biopharma	N/A	49.53 million	25.75 million	N/A
BCTX Briacell Therap	8	6.78 million	6.39 million	No Data
PASG Passage Bio	130	3.18 million	3.04 million	Optionable
PULM Pulmatrix	20	N/A	N/A	Not Optionable

BCTX, PASG, PULM, and ASBP Headlines

Recent News About These Companies

Short Interest in Pulmatrix, Inc. (NASDAQ:PULM) Expands By 51.2%

August 9, 2025 | americanbankingnews.com

Pulmatrix (PULM) Q2 Revenue Falls 100%

August 6, 2025 | fool.com

Pulmatrix Announces Second Quarter 2025 Financial Results and Divestment Plan for Inhalation Assets

August 6, 2025 | prnewswire.com

Pulmatrix Inc.

June 2, 2025 | barrons.com

Pulmatrix set for merger with Cullgen, seeks asset divestment

May 17, 2025 | uk.investing.com

Pulmatrix Inc.: Pulmatrix Announces First Quarter 2025 Financial Results and Divestment Plan for Assets

May 15, 2025 | finanznachrichten.de

Pulmatrix Announces First Quarter 2025 Financial Results and Divestment Plan for Assets

May 15, 2025 | prnewswire.com

Aspergillosis Market on Track for Major Expansion by 2034, According to DelveInsight | F2G, Pulmatrix, TFF Pharmaceuticals, Scynexis, Pulmocide

April 3, 2025 | theglobeandmail.com

Pulmatrix Reports 2024 Financials and Merger Plans

March 24, 2025 | tipranks.com

Pulmatrix Inc.: Pulmatrix Announces Year-End and Fourth Quarter 2024 Financial Results and Divestment Plan for Assets

March 21, 2025 | finanznachrichten.de

Pulmatrix Announces Year-End and Fourth Quarter 2024 Financial Results and Divestment Plan for Assets

March 21, 2025 | prnewswire.com

Pulmatrix revises bylaws, changes voting standards

February 14, 2025 | msn.com

Cullgen Begins Phase 1 Dosing of its Potential First-in-Class, Oral Pan-TRK Protein Degrader for Acute and Chronic Pain

January 23, 2025 | finance.yahoo.com

How to Take Advantage of moves in (PULM)

January 11, 2025 | news.stocktradersdaily.comN

When the Price of (PULM) Talks, People Listen

December 11, 2024 | news.stocktradersdaily.comN

Pulmatrix Inc (PULM) Stock: Surpassing Expectations in the Market

November 19, 2024 | bovnews.comB

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PULM and ENTO on Behalf of Shareholders

November 15, 2024 | accesswire.comA

SHAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Pulmatrix, Inc. – PULM

November 15, 2024 | bakersfield.comB

PULM INVESTOR ALERT: Rigrodsky Law, P.A. Is Investigating Pulmatrix, Inc. Merger

November 14, 2024 | accesswire.comA

SHAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Pulmatrix, Inc. – PULM

November 14, 2024 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

BCTX, PASG, PULM, and ASBP Company Descriptions

Aspire Biopharma NASDAQ:ASBP

$0.59 +0.23 (+64.35%)

As of 04:00 PM Eastern

Aspire Biopharma Holdings, Inc., early-stage biopharmaceutical company, engages in developing and marketing of disruptive technology for delivery mechanisms for do no harm drugs in the United States. The company provides Sublingual Aspirin Product, which addresses cardiology emergencies and pain management. It develops formulation for a sublingually administered melatonin sleep-aid product; vitamins D, E, and K; testosterone; and semaglutide, as well as formulations for anti-nausea products, anti-psychotic products, ED drugs, seizure medication, and several other classes of drugs. The company was founded in 2021 and is based in Humacao, Puerto Rico.

Briacell Therap NASDAQ:BCTX

$0.76 +0.02 (+3.11%)

Closing price 04:00 PM Eastern

Extended Trading

$0.76 -0.01 (-0.79%)

As of 04:38 PM Eastern

BriaCell Therapeutics Corp., a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer. The company is also developing Bria-OTS, a platform of personalized off-the-shelf cell-based immunotherapies, which is being evaluated in a Phase 1/2 clinical studies targeting breast cancer with extension to prostate cancer and other cancers. BriaCell Therapeutics Corp. is based in West Vancouver, Canada.

Passage Bio NASDAQ:PASG

$7.22 +0.27 (+3.88%)

Closing price 04:00 PM Eastern

Extended Trading

$7.14 -0.08 (-1.04%)

As of 04:10 PM Eastern

Passage Bio, Inc., a genetic medicines company, develops gene therapies for central nervous system diseases. It develops PBGM01, a functional GLB1 gene encoding ß-galactosidase for infantile GM1; PBFT02, a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD caused by progranulin deficiency; and PBKR03, a functional GALC gene encoding the hydrolytic enzyme galactosylceramidase for infantile Krabbe disease. The company develops PBML04 for the treatment of metachromatic leukodystrophy; PBAL05 for the treatment of amyotrophic lateral sclerosis; and other program for huntington's disease. It has a strategic research collaboration with the Trustees of the University of Pennsylvania's Gene Therapy Program; and collaboration agreement, and a development services and clinical supply agreement with Catalent Maryland, Inc. Passage Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.

Pulmatrix NASDAQ:PULM

$4.76 +0.05 (+0.98%)

As of 04:00 PM Eastern

Pulmatrix, Inc., a clinical stage biotechnology company, focused on development of novel inhaled therapeutic products to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. It engages in developing PUR1800, a narrow spectrum kinase inhibitor completed Phase 1b clinical trials for the treatment of acute exacerbations in chronic obstructive pulmonary disease; PUR1900 for the treatment of allergic bronchopulmonary aspergillosis in patients with asthma and cystic fibrosis; and PUR3100, an iSPERSE formulation of dihydroergotamine which is in Phase 1 for the treatment of acute migraine. It has a license agreement with RespiVert Ltd. for access to a portfolio of kinase inhibitor drug candidates. The company was founded in 2003 and is headquartered in Bedford, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time